IMVT - CIK 0001764013
The table below shows Immunovant, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | $101.81M | $68.60M |
| SG&A | $76.24M | $77.23M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $57.28M |
| $48.02M |
| $54.23M |
| $39.51M |
| Operating income | - | - | - | - | - | - |
| Income tax | $215.00K | $891.00K | $567.00K | $9.00K | -$84.00K | -$358.00K |
| Net income | -$505.61M | -$413.84M | -$259.34M | -$210.96M | -$156.73M | -$107.43M |
| EPS (diluted) | -$2.77 | -$2.73 | -$1.88 | -$1.71 | -$1.43 | -$1.22 |